enGene Holdings Inc.
ENGNHealthcare|Biotechnology|CA
$1.75
+0.07 (+4.17%)
DCF Value
$0.28
Tangible Book / Share
$3.30
Cash / Share
$3.82
About
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Stock Price
-70.9%(1Y)
1M
-1.7%
3M
-2.8%
6M
+16.7%
YTD
-80.6%
1Y
-70.9%
3Y
-79.4%
5Y
-91.3%
Pipeline Summary
1 total trials1
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722Superficial Bladder Cancer
Phase 1Phase 2Recruiting
Enrollment: 350 participants
Key Facts
Market Cap$117.3M
Employees81 (+45% YoY)
CEORonald H. W. Cooper
IPO DateFeb 1, 2022
Beta-0.28
52-Week Range$1.4 – $12.25
Avg Volume821,046
ExchangeNASDAQ
Websiteengene.com
Ownership
Float36.6%
Shares Outstanding67.0M
Recent Insider Trades
Grossman WilliamBUY
Sep 22, 20265,102 shares @ $1.97
Chinoporos ConstantineOTHER
Jul 16, 202675,000 shares @ $1.75
Richton Kathleen P.OTHER
Jul 16, 20260 shares
Richton Kathleen P.OTHER
Jul 16, 202645,000 shares @ $7.39
Richton Kathleen P.OTHER
Jul 16, 202613,900 shares @ $9.53
Peers
Recent News
enGene to Participate in Upcoming Investor Conferences
Nov 6, 2026 · businesswire.com
enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Price Target of $11.05 According to Brokerages
Nov 6, 2026 · defenseworld.net
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
Oct 16, 2026 · marketbeat.com
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
Oct 15, 2026 · seekingalpha.com
enGene to Host KOL Webinar on October 15, 2026
Oct 13, 2026 · businesswire.com
Data last updated: Nov 9, 2026, 04:08 AM